About Repair biotechnologies
Repair Biotechnologies: Revolutionizing Healthcare with Cholesterol Degrading Platform (CDP) Therapy
Repair Biotechnologies is a biotech company that is dedicated to revolutionizing healthcare by developing innovative therapies for chronic and orphan diseases. The company's focus is on developing a cholesterol degrading platform (CDP) therapy that can help treat several diseases caused by the accumulation of cholesterol in the body.
Human cells cannot degrade cholesterol, which leads to several chronic and orphan diseases such as atherosclerosis, Alzheimer's disease, Niemann-Pick disease type C, and Smith-Lemli-Opitz syndrome. These diseases are caused by the accumulation of cholesterol in different parts of the body such as blood vessels, brain cells, liver cells, and skin cells.
Repair Biotechnologies' CDP therapy aims to solve this problem by using enzymes that can break down cholesterol into harmless molecules that can be easily eliminated from the body. The therapy involves injecting these enzymes into the patient's bloodstream or directly into affected tissues to reduce the buildup of cholesterol.
The company has made significant progress in developing this therapy and has already conducted preclinical studies on animal models. The results have been promising so far, with significant reductions in cholesterol levels observed in treated animals.
Apart from its CDP therapy program, Repair Biotechnologies also has other research programs focused on aging-related diseases such as sarcopenia (muscle loss), osteoporosis (bone loss), and frailty. These programs aim to develop therapies that can slow down or reverse age-related degeneration processes.
The company was founded by Reason Bradley and Bill Cherman in 2018 with a mission to develop innovative therapies for age-related diseases. Both founders have extensive experience in biotech startups and are passionate about using science to improve human health.
Repair Biotechnologies' team consists of experienced scientists who are experts in their respective fields such as biochemistry, molecular biology, pharmacology, and drug development. The team is dedicated to developing safe and effective therapies that can improve the quality of life for patients suffering from chronic and orphan diseases.
The company has received funding from several sources such as angel investors, venture capitalists, and grants from government agencies such as the National Institutes of Health (NIH). This funding has enabled Repair Biotechnologies to conduct preclinical studies on its CDP therapy program and advance its research programs in aging-related diseases.
In conclusion, Repair Biotechnologies is a biotech company that is dedicated to revolutionizing healthcare by developing innovative therapies for chronic and orphan diseases. Its cholesterol degrading platform (CDP) therapy program aims to solve the problem of cholesterol accumulation in the body, which leads to several debilitating diseases. The company's other research programs focused on aging-related diseases also hold promise for developing therapies that can slow down or reverse age-related degeneration processes. With a team of experienced scientists and funding from various sources, Repair Biotechnologies is well-positioned to make significant contributions to improving human health.